Dreem

Dreem is the development of Rythm company in the field of neurotechnologies designed to increase sleep quality.

The ergonomic device is equipped special with sensors (electrodes for electroencephalography/EEG) which allow Dreem to monitor independently activity of a brain during sleep, fixing its electroimpulses and at the same time tracing such parameters as pulse, frequency of breath, movement in a dream.

Dreem. Photo: venturebeat.com

The gadget carries out the analysis of data retrieveds in real time and then, taking into account collected information, sends directly to an inner ear silent and accurate sound signals for improvement of sleep quality.

Dreem functions in a tandem with the intuitive mobile application allowing users to carry out the personalized setup of the device: activate/deactivate functions, change the volume of sound, time of activation and a tune of the built-in alarm clock and so forth. The application will also provide to the user statistics in which all indicators of its user are collected, and will offer the customized hints on improvement of sleep quality.

Technical characteristics (as of June, 2018)

• Weight: 120 g
• Technologies of connection: Bluetooth 4.0 Low Energy, Micro USB (only for recharge of the gadget), Wi-Fi b/g/n (2.4Ghz and 5.0Ghz)
• Audio: Bone Conductor system (3.5 mm), audioconnector
• Recharge time: 2-2.5 hours (up to 100%)
• Materials: hypoallergenic
• Compatibility: support of IOS 9.0, Android 4.3+, iPod (the 5th generation above)
• Interface: touchpad, LED indicator
• Accumulator: 1200 mAh, support operation of the device within 12 hours
• Sensors: 6 electrodes for EEG, the pulseoxymeter, the accelerometer

Development History

2018: Attraction of $35 million investments

The French startup of Rythm announced on June 26, 2018 attraction of $35 million investments during a financing round which was headed by the American company Johnson&Johnson and the French State Bank of Bpifrance, VentureBeat tells.

Developers of a bandage for monitoring of a dream attracted $35 million investments

The company is going to spend the received funds for further development and improvement of the innovation product Dreem intended for quality improvement of a dream and also a research in this area. At the same time the part of funds of Rythm intends to allocate for a staff increase of employees which contains, as of June, 70 people.

The Dreem device developed by the company is capable to monitor automatically bioelectric activity of a brain during sleep and to give the sound signals allowing to fall asleep quicker and increasing dream depth. In general the gadget, according to Hugo Mercier, CEO Rythm, is aimed at problem solving with a dream which test 30% of the population of Earth.

From the moment of the foundation in 2013 the Rythm company in general could attract about $60 million investments. Earlier the French businessman Xavier Niel and the French MAIF company of insurance became investors of the company.^[1]

2017: Device presentation

In June, 2017 the Rythm company officially provided a bandage for a dream of Dreem and announced the beginning of acceptance of preorders for the product.

In comparison with the beta, the commercial version of Dreem underwent changes: it is more compact, easy and offers more functions.

Dreem (2017)

2016: Start of the beta

In June, 2016 the Rythm company startup which saved up by that moment of 12 million euros started beta veriyu the product Dreem is bandages for quality improvement of a dream. 500 people from France, the USA and Great Britain took part in beta testing. Information provided by participants of testing gathered within 6 months. All Rythm using Dreem it was succeeded to analyze data about more than 45 thousand dreams.

The Dreem First program during which beta testing of the product Dreem was carried out

Notes